A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
Status:
Unknown status
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents
have been claimed equivalent in treatment, there are no head to head trials available in the
literature about there effectiveness in HBV Decompensated Cirrhosis. The investigators aimed
to compare safety/efficacy and virological response in patients with HBV Decompensated
Cirrhosis.